Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis

RCT (n=86) reports rilonacept led to rapid resolution of recurrent pericarditis episodes and to a significantly lower risk of pericarditis recurrence than placebo; 2 of 30 patients (7%) in rilonacept group had pericarditis recurrence vs. 23 of 31 patients (74%) in placebo group.

Source:

New England Journal of Medicine